Literature DB >> 22323578

TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?

G B Migliori1, G Sotgiu, L D'Ambrosio, R Centis, C Lange, G Bothamley, D M Cirillo, S De Lorenzo, G Guenther, K Kliiman, R Muetterlein, V Spinu, M Villar, J P Zellweger, A Sandgren, E Huitric, D Manissero.   

Abstract

In spite of the growing awareness of emerging drug-resistant Mycobacterium tuberculosis, the extent of inappropriate tuberculosis (TB) case management may be underestimated, even in Europe. We evaluated TB case management in the European Union/European Economic Area countries, with special focus on multidrug-resistant (MDR) and extensively drug-resistant (XDR)-TB, using a purposely developed, standardised survey tool. National reference centres in five countries representing different geographical, socioeconomic and epidemiological patterns of TB in Europe were surveyed. 40 consecutive, original clinical TB case records (30 MDR/XDR-TB cases) were reviewed in each of the five countries. The findings were recorded and, through the survey tool, compared with previously agreed and identified international standards. Deviations from international standards of TB care were observed in the following areas: surveillance (no information available on patient outcomes); infection control (lack of respiratory isolation rooms/procedures and negative-pressure ventilation rooms); clinical management of TB, MDR-TB and HIV co-infection (inadequate bacteriological diagnosis, regimen selection and treatment duration); laboratory support; and diagnostic/treatment algorithms. Gaps between present international standards of care and the management of MDR/XDR-TB patients were identified. Training, increased awareness, promotion of standards and allocation of appropriate resources are necessary to ensure appropriate care and management as well as to prevent further emergence of drug resistance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22323578     DOI: 10.1183/09031936.00170411

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  21 in total

1.  A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium.

Authors:  Lia D'Ambrosio; Marina Tadolini; Rosella Centis; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

2.  The multidrug-resistant tuberculosis threat: old problems and new solutions.

Authors:  Giovanni Sotgiu; Lia D'Ambrosio; Rosella Centis; Ida Mura; Paolo Castiglia; Antonio Spanevello; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

3.  Performance of a lateral flow immunochromatography test for the rapid diagnosis of active tuberculosis in a large multicentre study in areas with different clinical settings and tuberculosis exposure levels.

Authors:  Selene Manga; Rocio Perales; Maria Reaño; Lia D'Ambrosio; Giovanni Battista Migliori; Massimo Amicosante
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 4.  Agents of change: The role of healthcare workers in the prevention of nosocomial and occupational tuberculosis.

Authors:  Ruvandhi R Nathavitharana; Patricia Bond; Angela Dramowski; Koot Kotze; Philip Lederer; Ingrid Oxley; Jurgens A Peters; Chanel Rossouw; Helene-Mari van der Westhuizen; Bart Willems; Tiong Xun Ting; Arne von Delft; Dalene von Delft; Raquel Duarte; Edward Nardell; Alimuddin Zumla
Journal:  Presse Med       Date:  2017-02-28       Impact factor: 1.228

5.  Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.

Authors:  G B Migliori; G Sotgiu; N R Gandhi; D Falzon; K DeRiemer; R Centis; M G Hollm-Delgado; D Palmero; C Pérez-Guzmán; M H Vargas; L D'Ambrosio; A Spanevello; M Bauer; E D Chan; H S Schaaf; S Keshavjee; T H Holtz; D Menzies
Journal:  Eur Respir J       Date:  2012-10-11       Impact factor: 16.671

Review 6.  Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones.

Authors:  Giovanni Battista Migliori; Miranda W Langendam; Lia D'Ambrosio; Rosella Centis; Francesco Blasi; Emma Huitric; Davide Manissero; Marieke J van der Werf
Journal:  Eur Respir J       Date:  2012-05-31       Impact factor: 16.671

7.  European union standards for tuberculosis care.

Authors:  G B Migliori; J P Zellweger; I Abubakar; E Ibraim; J A Caminero; G De Vries; L D'Ambrosio; R Centis; G Sotgiu; O Menegale; K Kliiman; T Aksamit; D M Cirillo; M Danilovits; M Dara; K Dheda; A T Dinh-Xuan; H Kluge; C Lange; V Leimane; R Loddenkemper; L P Nicod; M C Raviglione; A Spanevello; V Ø Thomsen; M Villar; M Wanlin; J A Wedzicha; A Zumla; F Blasi; E Huitric; A Sandgren; D Manissero
Journal:  Eur Respir J       Date:  2012-04       Impact factor: 16.671

Review 8.  Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement.

Authors:  Masoud Dara; Pierpaolo de Colombani; Roumyana Petrova-Benedict; Rosella Centis; Jean-Pierre Zellweger; Andreas Sandgren; Einar Heldal; Giovanni Sotgiu; Niesje Jansen; Rankica Bahtijarevic; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2012-05-31       Impact factor: 16.671

9.  TBNET - Collaborative research on tuberculosis in Europe.

Authors:  C Giehl; C Lange; R Duarte; G Bothamley; C Gerlach; D M Cirillo; D Wagner; B Kampmann; D Goletti; T Juers; M Sester
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-12-11

10.  Multidisciplinary management of difficult-to-treat drug resistant tuberculosis: a review of cases presented to the national consilium in Uganda.

Authors:  Joseph Baruch Baluku; Richard Katuramu; Joshua Naloka; Enock Kizito; Martin Nabwana; Felix Bongomin
Journal:  BMC Pulm Med       Date:  2021-07-10       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.